



REVOLUTIONIZING SUN PROTECTION

THROUGH A UNIQUE
BIOTECH PLATFORM

APRIL 2026

DISCLAIMER



This presentation has been prepared by SKINOSIVE (the “Company”) solely for use in investor presentations. By receiving this presentation and participating in this meeting, you acknowledge that you have read and understood the following restrictions.

This presentation does not constitute, nor is it part of, any offer or invitation to sell or subscribe for securities. Neither this document nor any part thereof constitutes the basis of any contract or commitment, and must not be relied upon in support of any such contract or commitment. Any decision to acquire or subscribe for securities in connection with any future offer may only be made on the basis of the information contained in a Prospectus submitted for approval to the *Autorité des marchés financiers* or in any other offering document that may then be prepared and issued by the Company in connection with such offer.


This presentation is provided to you on a personal basis solely for your information and is to be used only for the purposes of the Company’s presentation. This presentation and its contents are confidential and may not be copied, distributed or transmitted to any other person, or published or reproduced, directly or indirectly, in whole or in part, by any means, in any form and for any purpose whatsoever. You must comply with all laws applicable to the possession of such information, including insider trading laws. Neither this presentation, nor a copy thereof, nor any information contained herein may be brought into, communicated or distributed, directly or indirectly, in the United States, Canada, Japan or Australia, or to any resident of those countries. Failure to comply with any of these restrictions may constitute a breach of legal restrictions on the offer of financial instruments in the United States, Canada, Japan or Australia. The distribution of this document in other countries may be subject to legal restrictions, and persons who come into possession of it must inform themselves as to the existence of such restrictions and comply with them.

This presentation has been prepared by, and is the sole responsibility of, the Company. The information set out below has not been independently verified by the Company, its advisers or any other person and may be subject to updates, additions and revisions, which may be material. No express or implied representation or warranty is given as to the accuracy, truthfulness, completeness or relevance of the information contained in this document. The Company, its advisers and their representatives shall not be liable for any loss arising from any use made of this presentation or its contents, or in any way connected with this presentation. The Company is under no obligation to update or revise the information contained in this presentation, and any information contained herein is subject to change without prior notice.

This presentation contains forward-looking statements regarding the Company’s objectives and strategic priorities. Such statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking terms such as “expect”, “may”, “estimate”, “intend”, “plan”, “anticipate” and other similar terms. These statements are subject to risks and uncertainties which may result, in the future, in actual results differing materially from those stated. These objectives and development priorities are not historical data and should not be interpreted as guarantees that the facts and figures stated will occur, that the assumptions will be verified, or that the objectives will be achieved. By their very nature, these objectives may not be achieved and the statements or information contained in this presentation may prove to be incorrect, without the Company, its advisers and their representatives being subject in any way to an obligation to update them, subject to applicable regulations.

SKIN CANCER

MOST COMMON CANCER IN WESTERN COUNTRIES*, WITH CONTINUING INCREASE IN INCIDENCE



**1.56 MILLION
NEW CASES
PER YEAR****

**1 IN 5 PEOPLE WILL DEVELOP
SKIN CANCER
IN THE NEXT DECADE****

**80% OF MELANOMA CASES
RELATED TO UV EXPOSURE*****

* In North America, Australia, New Zealand, and Western and Northern Europe, MARCH 2022 – GLOBOCAN; ** Data from the Skin Cancer Foundation, 2025 (United States); ***IARC 2025



SUN PROTECTION (UV FILTERS)
REMAINS THE FIRST PREVENTION SOLUTION

CURRENT SUN PROTECTION... **INADEQUATE AND INSUFFICIENT**

LIMITATIONS OF CURRENT UV FILTERS

NEED TO REAPPLY EVERY TWO HOURS

- ... most of the time not respected—very inconvenient
- Low EFFICACY due to lack of adhesion to the skin

POTENTIAL HEALTH RISKS: ABSORPTION IN THE BODY & DIFFUSION

- Diffusion to the eyes and eye irritation
- Current filters monitored by the authorities: penetration and toxicity
- Proposed FDA Monograph Order: risk for major restriction of some UV Filters in the USA*

COMPANIES IN THE SECTOR SPEND ONLY 3% OF THEIR REVENUE ON INNOVATION



25 YEARS WITHOUT MAJOR INNOVATION!



MAJOR NEED FOR INNOVATION FOR MORE EFFECTIVE AND SAFER PROTECTION

SKINOSIVE BIO-ADHESION

LONG-LASTING AND SAFE UV FILTERS



SKINOSIVE'S BIO-ADHESIVE UV FILTERS

ONLY ONE APPLICATION PER DAY

- ✓ SKIN ADHESION
- ✓ EXTENDED PROTECTION
UP TO 8 HOURS

BETTER TOLERANCE

- ✓ NO DIFFUSION TO EYES
- ✓ NO SKIN PENETRATION




A REVOLUTION IN SUN PROTECTION

SKINOSIVE BIO-ADHESIVE UV FILTERS


A REVOLUTIONARY PLATFORM

FOR GENERATING LONG-LASTING & SAFE UV FILTERS



* INCI: International Nomenclature Cosmetic Ingredient

SKINOSIVE COMBINES EXISTING UV FILTERS WITH A PROPRIETARY BIOADHESIVE GROUP



DHMB / M10 - Diethylamino Hydroxybenzoyl
Maleimidopropylamidoethyl Benzoate

Black: UV filter part
Blue: bio-adhesive part

- 01.** The surface of the skin naturally contains proteins with thiol groups (S-H)
- 02.** Skinosive's patented UV filters contain a bio adhesive group that forms a covalent chemical bond with thiol (S-H) groups on the skin's surface
- 03.** Skinosive's UV filters adhere specifically to the skin and remain present on the surface without penetrating it: **long-lasting efficacy and better tolerability**

PORTFOLIO OF 4 UV FILTERS:

- M10 filter (UVA; INCI*: DHMB)
- OOM filter (UVB, INCI: PCD)
- EHM filter (UVB, INCI: DMT)
- BEMT-Mal Filter (UVA-B)

TARGETED PROTECTION:

SPF50+ for the market thanks to the combination of the 4 bio-adhesive filters

MAJOR BENEFITS OF BIO-ADHESION

DEMONSTRATED IN INTERNATIONAL CLINICAL STUDIES



UP TO 8-HOUR SKIN ADHERENCE CLINICALLY DEMONSTRATED




OBJECTIVE

8-hour persistence of UV filters on the skin surface by FTIR spectroscopy

METHODS

15 FTIR spectroscopy measurements (immediate, 2h, 4h, 8h)
3 healthy subjects



**DISAPPEARANCE
OF UV FILTERS**

**PERSISTENCE OF
PRESENCE
UV FILTERS
98%**
FOR OPTIMAL
PROTECTION

5 CLINICAL STUDIES EXCEEDING DERMO-COSMETIC STANDARDS, CONDUCTED WITH INTERNATIONALLY RENOWNED CROs

OBJECTIVES	BIOADHESION & PERSISTENCE (8H)	PERSISTENCE & RESISTANCE (6H)	MIGRATION & DIFFUSION (FACE)	SECURITY & NON-PENETRATION	SKIN TOLERANCE
METHODOLOGY	FTIR technology on human faces (3 volunteers)	Expanded sample UVA imaging (15 volunteers)	UVA imaging on the face (10 volunteers)	Confocal Raman spectroscopy in humans (10 volunteers)	Repeated Insult Patch Test on the M10 filter (50 volunteers)
RESULTS	98% of the filters present on the skin after 8 hours	83% persistence at 6hours 67% resistance to rubbing	No migration to the eyes and mouth	Absence of skin penetration	Absence of irritant or sensitizing potential
PARTNER					
COUNTRY	UNITED STATES	FRANCE		GERMANY	SPAIN

A GROWING MARKET

DESPITE NO INNOVATION AND MOSTLY DRIVEN BY THE NEED TO PROTECT FROM THE SUN

DYNAMIC AND GROWING GLOBAL MARKET ...

SUNSCREEN:
\$11.9 BILLION IN 2024**

A CAGR OF +4.5%
UNTIL 2033**

GEOGRAPHICAL DISTRIBUTION OF MARKET SHARE**

ZONE	MARKET SIZE	MARKET SHARE	POSIT. PRICE	84% OF THE GLOBAL MARKET
USA	\$3.5bn	31%	+	
EUROPE	\$3.2bn	27%	+++	
ASIA	\$2.8bn	25%	++	
LATAM	\$1.2bn	10%	++	
MENA	\$0.82bn	7%	-	

...LACKING INNOVATION AND UNCOMPETITIVE***



- THE PREVENTION CAMPAIGNS ARE THE MAIN GROWTH DRIVER
- INCREMENTAL INNOVATIONS LIMITED TO FORMULATIONS AND SENSORIALITY
- ONLY 2 UV FILTERS RECENTLY APPROVED IN EUROPE:
2 APPLICATIONS SUBMITTED AND APPROVED IN EUROPE SINCE 2015
LAST APPROVAL IN THE UNITED STATES IN 1999

A UNIQUE MARKET OPPORTUNITY FOR SKINOSIVE

ESPECIALLY IN THE PREMIUM SEGMENT IN EUROPE

* Statista – Beauty & Personal Care – Global | Market forecasts. ΔCalculated; **Sunscreen market size, potential, and forecast; Sunscreen Size, Scope, Trends, Growth and Market Forecasts (Verified Market Research) *** Players ranking and geo market share may slightly vary according to years & market report

A MANAGEMENT TEAM OF INDUSTRY EXPERTS

AT THE SERVICE OF SKINOSIVE'S SUCCESS



BENOIT CANOLLE, PhD, MBA

CEO

20 years of experience in R&D and business development in the pharmaceutical industry



LISE AINIE, MSc

DIRECTOR OF R&D OPERATIONS

12 years of experience in clinical development in the cosmetics industry



JEAN MORTIER

CHAIRMAN OF THE BOARD OF DIRECTORS

- Graduate of ESSEC
- 30 years of experience
- President of Global Markets at Coty and former Chief Financial Officer of Unilever



AGNÈS MENUT

BUSINESS DEVELOPMENT DIRECTOR

Pharmacy and business school training
12 years in R&D at Sanofi



JULIETTE BERTRAND, PhD

DIRECTOR OF RESEARCH

- PhD in Cellular and Molecular Biology
- 9 years of experience in skin biology and photobiology



VINCENT DAGOMMER

CFO

Graduate of ESCP
Pharmaceutical industry, holding positions in business development and licensing



COMPLEMENTARITY OF TALENTS

FOR SHORT-TERM TIME-TO-MARKET

SKINOSIVE: SOLID FOUNDATION

TO REVOLUTIONIZE SUN PROTECTION



**DE-RISKED &
CLINICALLY PROVEN
TECHNOLOGY**

**STRONG INTELLECTUAL
PROPERTY
& FREEDOM TO OPERATE**

**\$12 BILLION & FAST-
GROWING MARKET**

**REPLICABLE
BIOTECH PLATFORM**
SKINCARE, BEAUTY, HAIR

FUNDING
€12.5M INVESTED, O/W
€1.4M IN SUBSIDIES



CONTACTS

Registered office: 12-14 Rue Jean Antoine de Baïf, 75013 Paris

Laboratory: 60 Avenue André Roussin, 13016 Marseille

CEO: Benoit Canolle, benoit.canolle@skinsosive.com